相关实验视频
在门诊瘤实践中实施症状管理干预措施的实施结果,使用集群随机阶段形试验设计进行评估
Justin D Smith1, Katy Bedjeti2, Nicola Lancki3
1Department of Population Health Science, Division of Health System Innovation and Research, Spencer Fox Eccles School of Medicine at the University of Utah, Salt Lake City, UT, USA. jd.smith@hsc.utah.edu.
Implementation science : IS
|December 3, 2025
概括
实施策略并没有显著增加患者采用电子健康记录 (EHR) 集成的癌症症状评估计划 (cPRO). 然而,一些策略可能会促进临床医生使用EHR点子短语来推症状管理.
科学领域:
- 实施科学 实施科学
- 数字健康数字健康
- 在瘤学瘤学.
背景情况:
- 电子健康记录 (EHR) 集成的计划旨在改善癌症症状管理.
- 该cPRO系统促进了在学术医疗机构的症状评估和管理.
研究的目的:
- 评估临床医生和系统级策略对cPRO计划的采用和影响的有效性.
- 评估实施策略对患者和临床医生参与cPRO的影响.
主要方法:
- 一个混合型2有效性-实施研究利用了一个集群随机化阶段式形试验设计.
- 六个集群的26个瘤诊所被随机分配到46个策略的逐步实施.
- 患者采用 (完成率) 和临床医生采用 (推使用) 分别是主要和次要结局.
主要成果:
- 在实施前和实施后期间之间,患者采用cPRO评估没有显著差异 (25%与40%对比).
- 实施策略没有显著改善患者入学范围 (RR=1.00,CI:0.78至1.27).
- 临床医生采用EHR点子短语推显示了边际的,非显著的积极关联 (RR=1.66,CI:0.79至3.48).
结论:
- 经过测试的实施策略并没有显著改善患者采用cPRO的情况.
- 策略可能为临床医生采用EHR集成的转诊功能提供潜在的好处.
- 需要进一步的研究来优化数字症状管理在癌症护理中的整合.
相关概念视频
Cancer Survival Analysis
630
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
630
Nursing Interventions II: Selecting and Classifying the Nursing Interventions
3.0K
Creating and executing a nursing diagnosis helps nurses plan care and guide patient, family, and community interventions. They are developed based on a patient's physical evaluation and support measuring the outcomes. It is not recommended to select random interventions throughout the planning process. Instead, consider the following six essential factors when choosing interventions:
3.0K
Guidelines for Writing Outcome
3.6K
When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
3.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
382
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
382
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K